{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:11:51Z","timestamp":1773033111757,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.parkreldis.2022.01.024","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T10:34:17Z","timestamp":1644057257000},"page":"29-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6943","authenticated-orcid":false,"given":"Ane","family":"Murueta-Goyena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9418-954X","authenticated-orcid":false,"given":"Raffaela","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-1005","authenticated-orcid":false,"given":"Mar","family":"Carmona-Abell\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Acera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naia","family":"Ayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Del Pino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Tijero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Fern\u00e1ndez-Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1igo","family":"Gabilondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-7748","authenticated-orcid":false,"given":"F\u00e1tima","family":"Zallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Matute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1144-9025","authenticated-orcid":false,"given":"Rosario","family":"S\u00e1nchez-Pernaute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-0495","authenticated-orcid":false,"given":"Estibaliz","family":"Capetillo-Zarate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4697-3890","authenticated-orcid":false,"given":"Juan Carlos","family":"G\u00f3mez-Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.parkreldis.2022.01.024_bib1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2022.01.024_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/PL00007856","article-title":"The heterogeneity of idiopathic Parkinson's disease","volume":"249","author":"Foltynie","year":"2002","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.01.024_bib3","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/s41467-020-19957-6","article-title":"Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies","volume":"11","author":"Mattsson-Carlgren","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.parkreldis.2022.01.024_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"issue":"9","key":"10.1016\/j.parkreldis.2022.01.024_bib5","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in Neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.01.024_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.22928","article-title":"Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment","volume":"25","author":"Duran","year":"2010","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2022.01.024_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","article-title":"The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy","volume":"113","author":"Lee","year":"2006","journal-title":"J. Neural. Transm."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.01.024_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123162","article-title":"Decrease in plasma levels of \u03b1-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference","volume":"10","author":"Ishii","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.parkreldis.2022.01.024_bib9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","article-title":"Plasma alpha-synuclein is decreased in subjects with Parkinson's disease","volume":"204","author":"Li","year":"2007","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.01.024_bib10","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for Parkinson's disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.01.024_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to \u03b1-Synuclein panel discriminates Parkinson's from controls","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.01.024_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2022.01.024_bib13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/mds.20581","article-title":"Abnormal sleep architecture is an early feature in the E46K familial synucleinopathy","volume":"20","author":"Zarranz","year":"2005","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2022.01.024_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2011.07.047","article-title":"Initial neuropsychological impairments in patients with the E46K mutation of the alpha-synuclein gene (PARK 1)","volume":"310","author":"Somme","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.parkreldis.2022.01.024_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1037\/a0012949","article-title":"Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies","volume":"22","author":"Hamilton","year":"2008","journal-title":"Neuropsychology"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.01.024_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1089\/neu.2017.5623","article-title":"Performance evaluation of a multiplex assay for simultaneous detection of four clinically relevant traumatic brain injury biomarkers","volume":"36","author":"Korley","year":"2018","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.parkreldis.2022.01.024_bib17","doi-asserted-by":"crossref","DOI":"10.3233\/JPD-212694","article-title":"Comparison of different platform immunoassays for the measurement of plasma alpha-synuclein in Parkinson's disease patients","author":"Youssef","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.parkreldis.2022.01.024_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164762","article-title":"CSF biomarkers and its associations with 18F-AV133 cerebral VMAT2 binding in Parkinson's disease-A preliminary report","volume":"11","author":"Gao","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.01.024_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2022.01.024_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.27284","article-title":"Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease","volume":"33","author":"Abbasi","year":"2018","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.01.024_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-020-00192-4","article-title":"CSF total and oligomeric \u03b1-Synuclein along with TNF-\u03b1 as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers","volume":"9","author":"Majbour","year":"2020","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.parkreldis.2022.01.024_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/mds.27884","article-title":"Parkinson's disease: glucocerebrosidase 1 mutation severity is associated with CSF alpha-synuclein profiles","volume":"35","author":"Lerche","year":"2020","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.01.024_bib23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"40","author":"Bougea","year":"2019","journal-title":"Neurol. Sci."},{"issue":"10","key":"10.1016\/j.parkreldis.2022.01.024_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e02590","article-title":"Alpha synuclein in hematopoiesis and immunity","volume":"5","author":"Pei","year":"2019","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.01.024_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-019-0499-6","article-title":"Reducing effect of insulin resistance on alpha-synuclein gene expression in skeletal muscle","volume":"11","author":"Khoshi","year":"2019","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.parkreldis.2022.01.024_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2020.03.014","article-title":"Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease","volume":"73","author":"Emmanouilidou","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2022.01.024_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.parkreldis.2019.05.038","article-title":"Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers","volume":"65","author":"Carmona-Abellan","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2022.01.024_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.parkreldis.2020.04.009","article-title":"Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease","volume":"74","author":"Sampedro","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.01.024_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clineuro.2011.11.002","article-title":"Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients","volume":"114","author":"Su","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"13","key":"10.1016\/j.parkreldis.2022.01.024_bib30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/WNL.0000000000007194","article-title":"High serum neurofilament light chain predicts a worse fate in early parkinsonism","volume":"92","author":"Akhtar","year":"2019","journal-title":"Neurology"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:24:57Z","timestamp":1761179097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802022000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":30,"alternative-id":["S1353802022000335"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.01.024","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}